Manshori Mahmood, Kazemnejad Somaieh, Naderi Nasim, Shirazi Abolfazl, Arabian Maedeh, Eghtedar Doost Marzieh, Darzi Maryam, Montazeri Samaneh, Aboutaleb Nahid, Golshahi Hannaneh
Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, Iran.
Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Avicenna J Med Biotechnol. 2023 Jul-Sep;15(3):157-166. doi: 10.18502/ajmb.v15i3.12924.
To evaluate the efficiency of Menstrual blood Stromal/Stem Cells (MenSCs) administration in Myocardial Infarction (MI), the effects of MenSCs and their derived conditioned Medium (CM) on cardiac function in MI rat model was assessed.
Animals were divided into four groups including sham group, MI group, MenSCs derived CM group (CM group), and MenSCs suspended in CM (MenSCs+CM) group. The injection of different groups was carried out 30 after ligation of left anterior descending coronary artery into the infarct border zone.
The results showed a significant reduction in scar size after injection of MenSCs+CM compared to MI group. Ejection fraction and fractional shortening of MenSCs+CM group were higher than CM and MI group at day 28. Administration of MenSCs+CM led to much more survival of cardiomyocytes, and prevention of meta-plastic development. Moreover, human mitochondrial transfer from MenSCs to cardiomyocytes was seen in group treated by MenSCs+CM. Indeed, MenSCs+CM treatment evoked nuclear factor-κB (NF-κB) down-regulation more than other treatments.
MenSCs+CM treatment could significantly ameliorate cardiac function by different mechanisms including inhibition of cartilaginous metaplasia, inhibition of NF-κB and mitochondrial transfer.
为评估月经血基质/干细胞(MenSCs)给药对心肌梗死(MI)的疗效,本研究评估了MenSCs及其条件培养基(CM)对MI大鼠模型心脏功能的影响。
将动物分为四组,包括假手术组、MI组、MenSCs条件培养基组(CM组)和悬浮于CM中的MenSCs组(MenSCs+CM组)。在结扎左冠状动脉前降支30分钟后,将不同组别的药物注射到梗死边缘区。
结果显示,与MI组相比,注射MenSCs+CM后瘢痕大小显著减小。在第28天时,MenSCs+CM组的射血分数和缩短分数高于CM组和MI组。给予MenSCs+CM可使更多心肌细胞存活,并防止化生发展。此外,在接受MenSCs+CM治疗的组中观察到了MenSCs的人线粒体向心肌细胞的转移。事实上,MenSCs+CM治疗比其他治疗更能引起核因子κB(NF-κB)的下调。
MenSCs+CM治疗可通过抑制软骨化生、抑制NF-κB和线粒体转移等不同机制显著改善心脏功能。